COA ↓

Product

COA Doc

SYN-2609

99.2% Purity SYN-2609 Research Grade HPLC Verified

Ipamorelin

Selective GH Secretagogue · Research Grade

Select Strength — 5mg

$50.00

C₃₈H₄₉N₉O₅ MW: 711.86 g/mol CAS: 170851-70-4

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.2%

HPLC Purity

Lot Number SYN-2609-IPA

Test Date March 2026

Labeled 10 mg

Actual 10.02 mg

99.5%

HPLC Purity

Lot Number SYN-2508-IPA

Test Date August 2025

Labeled 10 mg

Actual 10.05 mg

99.0%

HPLC Purity

Lot Number SYN-2401-IPA

Test Date January 2024

Labeled 10 mg

Actual 10.01 mg

Research Data

KEY FINDINGS

🧬

2.8×

GH Pulse Amplitude

vs. baseline in vitro GHSR-1a receptor activation studies

🔬

Cortisol / Prolactin Effect

No measurable cortisol or prolactin elevation — Raun et al., 1998

✅

99.2%

HPLC-Verified Purity

Current batch SYN-2609, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 Receptor Selectivity

Ipamorelin — The Cleanest GHRP

In this landmark 1998 study, Ipamorelin was demonstrated to be the most selective GHRP yet characterised — producing maximal GH release via GHSR-1a with no measurable effect on ACTH, cortisol, prolactin, or FSH in both rat and porcine models.

🔬 Ipamorelin is the only GHRP demonstrating full selectivity for the GH axis with zero concurrent cortisol or prolactin activation.

PMID 9671117 — Endocrinology

⚡ Synergistic Combination

CJC-1295 + Ipamorelin — Amplified Pulses

Combined GHRH/GHRP stimulation produces non-additive, synergistic GH secretion by simultaneously amplifying somatotroph pulse amplitude (via CJC-1295) and frequency (via Ipamorelin). The 5.8× GH pulse amplitude exceeds either compound alone.

🔬 Stack produces 5.8× GH amplitude — representing true synergy beyond the sum of individual effects (3.2× + 2.8× = 6.0×).

PMID 15253933 — Growth Hormone & IGF Research

📈 IGF-1 Modulation

Downstream IGF-1 Elevation

Repeated pulsatile GH stimulation via Ipamorelin produces dose-dependent IGF-1 elevation through hepatic JAK2-STAT5 signalling. IGF-1 increases of 1.7× above baseline have been consistently observed in pulsatile GH-stimulation models.

🔬 1.7× IGF-1 elevation with no cortisol co-elevation — the cleanest downstream anabolic signal of any injectable GHRP.

PMID 16352683 — J. Clin. Endocrinol. Metab.

2.8 ×

Selective GH Pulse Amplification

Ipamorelin stimulates GHSR-1a to produce clean GH pulses with 2.8× amplitude increase over baseline — with zero cortisol, ACTH, or prolactin co-elevation, distinguishing it from all other GHRPs in selectivity.

Hormone Selectivity — Ipamorelin vs. Other GHRPs

GH elevation (Ipamorelin) 2.8×

GH elevation (GHRP-2) 2.6×

Cortisol change 0.0×

Prolactin change 0.0×

Source: Raun K et al., Endocrinology, 1998 (PMID 9671117)

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2609-IPA

Specification	Value
CAS Number	170851-70-4
Molecular Formula	C₃₈H₄₉N₉O₅
Molecular Weight	711.86 g/mol
Purity (HPLC)	99.2%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

2.8 ×

GH Pulse Amplitude vs. Baseline (No Cortisol / Prolactin Elevation)

Ipamorelin (GHSR-1a) 2.8×

GHRP-2 (GHSR-1a) 2.6×

GHRP-6 (GHSR-1a) 2.2×

Untreated Baseline 1.0×

Comparative Activity Profile

Ipamorelin GHRP-6

Observed Adverse Indicators

Cortisol elevation

None

Prolactin elevation

None

Cytotoxicity at 1 nM

None

Off-target receptor binding

None

⚠️ Theoretical Concern

GH Axis Stimulation — Expected Research Effect

Ipamorelin stimulates GHSR-1a to produce pulsatile GH release. Researchers should account for downstream IGF-1 axis activation. This is the expected and intended effect — not an adverse finding.

No cortisol, ACTH, or prolactin elevation at any published effective dose — unique among all GHRPs
No cytotoxicity or off-target receptor binding in published in vitro models
Selective GHSR-1a agonism is the most extensively documented safety feature of Ipamorelin (Raun et al., 1998)

Ipamorelin

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

Ipamorelin — The Cleanest GHRP

CJC-1295 + Ipamorelin — Amplified Pulses

Downstream IGF-1 Elevation

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

GH Axis Stimulation — Expected Research Effect

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS